GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Asset Turnover

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Asset Turnover : 0.12 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Shenzhenlubris Pharmaceuticals Co's Revenue for the three months ended in Mar. 2024 was ¥1,091 Mil. Shenzhenlubris Pharmaceuticals Co's Total Assets for the quarter that ended in Mar. 2024 was ¥9,503 Mil. Therefore, Shenzhenlubris Pharmaceuticals Co's Asset Turnover for the quarter that ended in Mar. 2024 was 0.12.

Asset Turnover is linked to ROE % through Du Pont Formula. Shenzhenlubris Pharmaceuticals Co's annualized ROE % for the quarter that ended in Mar. 2024 was 9.86%. It is also linked to ROA % through Du Pont Formula. Shenzhenlubris Pharmaceuticals Co's annualized ROA % for the quarter that ended in Mar. 2024 was 8.43%.


Shenzhenlubris Pharmaceuticals Co Asset Turnover Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Asset Turnover Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.37 0.38 0.37 0.35

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.08 0.08 0.10 0.12

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Asset Turnover

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Asset Turnover falls into.



Shenzhenlubris Pharmaceuticals Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Shenzhenlubris Pharmaceuticals Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=3365.343/( (9755.269+9396.673)/ 2 )
=3365.343/9575.971
=0.35

Shenzhenlubris Pharmaceuticals Co's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1090.969/( (9396.673+9610.056)/ 2 )
=1090.969/9503.3645
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Shenzhenlubris Pharmaceuticals Co's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=801.06/8122.691
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(801.06 / 4363.876)*(4363.876 / 9503.3645)*(9503.3645/ 8122.691)
=Net Margin %*Asset Turnover*Equity Multiplier
=18.36 %*0.4592*1.17
=ROA %*Equity Multiplier
=8.43 %*1.17
=9.86 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Shenzhenlubris Pharmaceuticals Co's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=801.06/9503.3645
=(Net Income / Revenue)*(Revenue / Total Assets)
=(801.06 / 4363.876)*(4363.876 / 9503.3645)
=Net Margin %*Asset Turnover
=18.36 %*0.4592
=8.43 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Shenzhenlubris Pharmaceuticals Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines